OmniAb/$OABI
1D1W1MYTD1Y5YMAX
Capital at risk
About OmniAb
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
- Ticker
- $OABI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 89
- Headquarters
- EmeryVille, United States
- Website
- www.omniab.com
OmniAb Metrics
BasicAdvanced
$632M
-
-$0.35
1.22
-
Price and volume
Market cap
$632M
Beta
1.22
52-week high
$5.43
52-week low
$1.30
Average daily volume
2.1M
Financial strength
Current ratio
4.798
Quick ratio
4.53
Long term debt to equity
0.057
Total debt to equity
0.073
Profitability
EBITDA (TTM)
-21.596
Gross margin (TTM)
98.28%
Net profit margin (TTM)
-115.12%
Operating margin (TTM)
-101.74%
Effective tax rate (TTM)
3.15%
Revenue per employee (TTM)
$430,000
Management effectiveness
Return on assets (TTM)
-8.35%
Return on equity (TTM)
-16.95%
Valuation
Price to revenue (TTM)
14.134
Price to book
2.43
Price to tangible book (TTM)
10.5
Price to free cash flow (TTM)
-29.964
Free cash flow yield (TTM)
-3.34%
Free cash flow per share (TTM)
-0.145
Growth
Revenue change (TTM)
67.01%
Earnings per share change (TTM)
-41.57%
3-year revenue growth (CAGR)
-16.53%
3-year earnings per share growth (CAGR)
7.65%
Bulls say / Bears say
OmniAb Q2 revenue of $13.4 million exceeded the IBES estimate of $4.69 million, driven by stronger-than-expected milestone and service revenue from partner programs. (Reuters)
Management raised full-year 2026 revenue guidance to $32–36 million from $28–33 million, reflecting confidence in continued partner program momentum and recurring royalty streams. (Reuters)
OmniAb entered a global collaboration and license agreement with Eli Lilly for a new ion channel program, securing an upfront payment and up to $370 million in milestone payments plus tiered royalties, diversifying its high-value partnership portfolio. (Reuters)
Forty-quarter Q4 2025 revenue was $8.4 million, missing the IBES estimate of $9 million, underscoring the volatility of its milestone-driven revenue model. (Reuters)
Q4 2025 net loss of $14.2 million (−$0.11 per share) demonstrated ongoing unprofitability despite milestone gains, indicating persistent cash burn. (Reuters)
Q4 2025 revenue fell 22% year-over-year, highlighting the lumpy and unpredictable nature of license and milestone revenues. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
Upcoming events
No upcoming events
OmniAb News
AllArticlesVideos
Funds containing OmniAb
AllUSDGBPEUR
Fund name | Fund size | $OABI weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.